Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Novare Investments’ South African hedge fund survey asks: 'What will boost assets in the sector?’

Tuesday, October 01, 2013

Beverly Chandler, Opalesque London:

Novare Investment’s tenth edition of the South African hedge fund survey is a snapshot of all things pertaining to the South African hedge fund industry as as 30 June 2013. The data is drawn from 55 South African funds and includes 107 different mandated single strategy hedge funds. Highlights include:

  • The local hedge fund industry has surpassed the R40 billion assets mark, reaching a new all-time high.
  • 13 new funds were launched during the 12 months to end June, while 15 funds returned investor capital.
  • Equity long/short funds continued to dominate the local hedge fund industry with more than half of industry assets managed within this strategy.
  • The ten largest hedge funds as at 30 June 2013 managed 42.9% of total industry assets.
  • There is a rising trend amongst managers offering investors the option of investing in a share class charging a lower (or even zero) management fee, in combination with a higher performance fee.
  • Hedge funds with a track record exceeding eight years manage more than 50.0% of industry assets.
  • The equity long/short strategy was the best performing category over the period. Compared to exposure levels from a year prior, these funds on average also had higher gross and net equity market exposure levels over the past 12 months.
  • Close to half of the industry make use of an external or in......................

    To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for